Federal Register Notice: FDA has determined the regulatory review period for Otsuka Pharmaceutical’s Abilify (aripiprazole) indicated for the treatment of schizophrenia is 3,416 days. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product. To view this notice, click here.
